Avenue Therapeutics, Inc. (ATXI)
| Market Cap | 4.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.59M |
| Shares Out | 22.13M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | 17.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 327,783 |
| Open | 0.251 |
| Previous Close | 0.251 |
| Day's Range | 0.220 - 0.268 |
| 52-Week Range | 0.200 - 2.810 |
| Beta | 1.05 |
| Analysts | Sell |
| Price Target | n/a |
| Earnings Date | n/a |
About ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York. [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
No stock price forecast available yet.
News
Top Biotech Penny Stocks to Buy Now? 3 to Watch in March
Check these three biotech penny stocks out for your watchlist The post Top Biotech Penny Stocks to Buy Now? 3 to Watch in March appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...
Avenue Therapeutics Stock Trading Halted Today
FDA Advisory Committee to review IV tramadol New Drug Application FDA Advisory Committee to review IV tramadol New Drug Application
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics ...
NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeut...
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today an...
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock
NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...
Best Penny Stocks Today: Why ATXI & PTPI Stock Are Moving
Shares of penny stocks PTPI & ATXI are on the move and here's what's going on. The post Best Penny Stocks Today: Why ATXI & PTPI Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and I...
Avenue Therapeutics Announces Exercise and Closing of Underwriter's Over-Allotment Option
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today annou...
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutic...
NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therape...
Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Admini...
Office of New Drugs concludes that additional input is needed, and U.S. Food and Drug Administration will convene an Advisory Committee meeting Office of New Drugs concludes that additional input is nee...
Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday
Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COVID...
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investor...
Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?
Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...
Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...
Avenue Therapeutics' Pain Drug Gets Complete Response Letter
Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.
Avenue Therapeutics Sinks As FDA Rejects Opioid Pain Drug On Safety Concerns
Shares of micro-cap biopharma Avenue Therapeutics Inc (NASDAQ: ATXI) are plummeting on above-average volume after a binary event panned out against the company. What Happened: New York-based Avenue said...
Avenue Therapeutics Announces Publication of a Review of IV Tramadol
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announc...
Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2
Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported...
What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?
Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.
Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.